<DOC>
	<DOCNO>NCT00237848</DOCNO>
	<brief_summary>This study examine effectiveness D-serine increase sustain benefit cognitive retrain people schizophrenia .</brief_summary>
	<brief_title>D-Serine Enhancing Cognitive Retraining Treatment Schizophrenia</brief_title>
	<detailed_description>This study base hypothesis increase NMDA receptor function brain thereby increase capacity brain form new connection strengthen exist connection , schizophrenic patient may derive great sustain benefit cognitive retraining . Patients schizophrenia schizoaffective disorder currently receive antipsychotic medication randomly assign double-blind manner receive either D-serine ( 30 mg/kg ) placebo addition cognitive rehabilitation non-interactive placebo 12 week .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<criteria>Diagnosis schizophrenia schizoaffective disorder Clinically stable Treated antipsychotic medication least 6 month past , stable dose antipsychotic medication past month Not pregnant lactate Other current past DSMIV Axis I diagnosis Calgary Depression scale score &gt; 10 SimpsonAngus Rating Scale score &gt; 20 Currently treat clozapine , lamotrigine carbamazepine , define treatment refractory Substance abuse dependence within past 3 month , except nicotine Wechsler Adult Intelligence ScaleRevised score &lt; 70 Significant recent ( within past 3 month ) risk commit suicide Abnormal thyroid function test within last 6 month Previous treatment Dserine History evidence medical neurological condition would expose subject undue risk significant adverse event interfere assessment safety efficacy trial Clinically significant abnormal laboratory test result screen ECT treatment within past two month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2008</verification_date>
</DOC>